Article Text

Download PDFPDF
Gastric outlet obstruction with prostaglandin E1 infusion in congenital diaphragmatic hernia
  1. Andrea Togo1,
  2. David Stewart1,
  3. Amanda Moody1,
  4. Sebastian King2,3,
  5. Ruth K Armstrong1
  1. 1 Department of Neonatal Medicine, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
  2. 2 Paediatric Surgery, The Royal Children's Hospital, Parkville, Victoria, Australia
  3. 3 Murdoch Children's Research Institute, Parkville, Victoria, Australia
  1. Correspondence to Dr Andrea Togo, Department of Neonatal Medicine, The Royal Children's Hospital Melbourne, Parkville 3052, VIC, Australia; togoandrea{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Prostaglandin E1 (PGE1) is used globally in neonatal medicine to maintain patency of the ductus arteriosus in duct-dependent congenital heart disease. Due to its non-selective pulmonary vasodilator effect and its role in offloading the pressure on the right ventricle via the ductus arteriosus, PGE1 has been increasingly used in the management of neonatal pulmonary hypertension, especially in those patients with congenital diaphragmatic hernia (CDH).1 2 Gastric outlet obstruction (GOO) has been described as a side effect of PGE1 in populations with congenital heart disease, most commonly secondary to hypertrophic pyloric stenosis (HPS) or antral foveolar hyperplasia (AFH).3

To describe our experience with the use of PGE1 in the CDH population and occurrence of GOO, we conducted a single-centre retrospective study of all …

View Full Text


  • Contributors AT designed the study, collected the data and prepared the manuscript. DS, AM, SK and RKA contributed to the editing of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.